Haemorrhagic cystitis is a common and often debilitating complication of chemotherapy for which treatment is frequently unsatisfactory. With over 80 cases reported of radiation-induced cystitis treated successfully with hyperbaric oxygen, attention is now turning to the treatment of chemotherapeutic agent-induced cystitis. We report a case of haemorrhagic cystitis occurring after autologous peripheral blood stem cell transplantation for multiple myeloma. The patient had received cyclophosphamide and busulfan and had BK and adenoviruria. The haemorrhage was refractory to multiple conventional treatments but resolved after a course of hyperbaric oxygen. Keywords: haemorrhagic cystitis; hyperbaric oxygen; cyclophosphamide; adenovirus; BK virus Hyperbaric oxygen was administered in a multiplace chamber. The treatment plan was based on that which would be used to treat radiation-induced cystitis.
Hyperbaric oxygen was administered in a multiplace chamber. The treatment plan was based on that which would be used to treat radiation-induced cystitis.
1,2 The patient received 100% oxygen for 80 min at an absolute pressure of 2.4 atmospheres. The total duration of each treatment was 99 min. One treatment per day was administered, 5 to 6 days per week. The end-point for treatment was resolution of haematuria.
Case history
A 41-year-old man was diagnosed with multiple myeloma in August 1995 after presenting with sudden onset of backpain. Bone marrow examination showed 32% plasma cells and an IgG paraprotein of 30 g/l was present in the serum. On the 5th post-transplant day, the patient became febrile and developed dysuria. The urine was noted to be rosé in colour. He was started on anti-bacterial antibiotics and urine was sent for BK virus, adenovirus and CMV isolation. By the 8th post-transplant day, he had progressed to severe bladder spasms and gross haematuria. A clinical diagnosis of haemorrhagic cystitis was made.
An indwelling catheter was inserted. Continuous bladder irrigation was commenced. Adenovirus was cultured from the urine on the 13th post-transplant day and PCR for BK virus was weakly positive. Engraftment occurred on the 14th post-transplant day. On the 15th day, alum (1% solution) washouts were commenced and were continued for 1 week. By the 22nd day, haemorrhage was still uncontrolled requiring the introduction of intravesical prostaglandin F2 alpha (PGF2 alpha) 200 g in 50 ml normal saline instilled for 1 h or as long as tolerated. This was repeated at 4 hourly intervals. PGF2 alpha was poorly tolerated by the patient due to extreme pain and was subsequently performed in the operating room under general anaesthesia. PGF2 alpha was continued for a further 5 days with no benefit. On the 24th day the patient underwent flexible cystoscopy which confirmed widespread mucosal ulceration consistent with haemorrhagic cystitis. From the 27th to the 37th day, the patient was treated with intravenous ribavirin (9 mg/kg intravenously 8 hourly) during which time his fever settled but haematuria continued. The patient underwent rigid cystoscopy, diathermy and instillation of silver nitrate on the 33rd day. Alum irrigation was recommenced following cessation of ribavirin but haematuria continued unabated.
The patient was then referred to the Hyperbaric Service and a course of 40 treatments in the hyperbaric chamber was planned. He underwent his first hyperbaric oxygen treatment on the 46th day post-transplant. He tolerated this well and continued with daily treatment as an outpatient. On the 70th day post-transplant, he experienced his first passage of non-bloodstained urine. He went on to complete a total of 37 treatments with complete resolution of haematuria and a marked reduction in dysuria.
He is now 14 months post-transplant and remains free of haematuria although he has some ongoing frequency and nocturia related to reduced bladder capacity. The myeloma remains in a stable partial remission on interferon alpha 2b maintenance treatment.
Discussion
Haemorrhagic cystitis was first recognised as a complication of treatment with cyclophosphamide in 1959 3 and was subsequently observed to be predisposed to by a wide range of agents, including busulfan. 4 Its course is often mild and transient but is occasionally chronic and may be associated with significant morbidity and blood loss. More recently, BK and adenovirus have been observed to cause an often self-limiting haemorrhagic cystitis in renal transplant patients. In bone marrow transplant patients, adenovirus-associated haemorrhagic cystitis has been observed to be of late onset and long duration, ranging from 7 to 81 days. Spontaneous resolution has been observed and may have explained the symptomatic improvement in our patient. 5, 6 Previous treatments reported for haemorrhagic cystitis include intravesical alum, silver nitrate, formalin and PGF2 alpha. 7 Such treatments are only moderately successful at controlling haemorrhage, do not modify the underlying disease process and the latter two are associated with significant morbidity. Ribavirin is a specific, although experimental, treatment for adenovirus-induced cystitis. 8 Radiation-induced cystitis causes diffuse mucosal oedema which may lead to progressive, obliterative endarteritis resulting in acute and chronic ischaemia of the bladder wall. Forni and Koss 9 defined the cytology and histology of cyclophosphamide-induced bladder toxicity, concluding that bladder wash cytology mimics that seen in irradiated patients. Histopathologically, cyclophosphamide-induced bladder damage is similar to radiation cystitis. Busulfan has been reported to produce cystitis indistinguishable from cyclophosphamide. 4 Thus, it would seem that although the mechanism of injury varies widely and in some cases is known to be due to a specific metabolite, the resultant damage is nonspecific.
Hyperbaric oxygen is a relatively new treatment for radiation cystitis. There have been several prospective studies of radiation-induced cystitis treated with hyperbaric oxygen. 10, 11 These have shown a beneficial effect on cystitis that was refractory to all previous treatments.
The proposed mechanism of action of hyperbaric oxygen is elevation of the oxygen gradient between the damaged, hypoxic urothelium and the normal tissues surrounding it. This stimulates macrophage invasion, production of macrophage-derived angiogenesis factor and other macrophagederived growth factors. These in turn stimulate angiogenesis. Thus this is the first available treatment that is potentially disease-modifying.
Recently Hader et al 12 reported a rat model of acroleininduced cystitis and concluded that exposure to hyperbaric oxygen increased the amount of intact urothelium. Two case reports have recently been published in which cyclophosphamide-induced cystitis was treated successfully with hyperbaric oxygen. 13, 14 Both cases had failed several conservative treatments before hyperbaric oxygen was used.
Chemotherapeutic agent-induced cystitis is a disease associated with significant morbidity. Hyperbaric oxygen is an effective, disease-modifying treatment for radiationinduced cystitis. The use of hyperbaric oxygen in chemotherapy-induced cystitis warrants further investigation with a prospective study.
